| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689397 | European Urology | 2016 | 9 Pages |
Abstract
Patients with metastatic castration-resistant prostate cancer-including those with or without visceral disease or widespread bone disease-benefitted from enzalutamide, an active well-tolerated therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Christopher P. Evans, Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, Choung-Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N. Sternberg, Yohann Loriot, Johann de Bono, Sarah B. Noonberg, Hank Mansbach,